Impact of dietary aflatoxin on immune development in Gambian infants: a cohort study.
epidemiology
immunology
nutrition
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
20 07 2021
20 07 2021
Historique:
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
5
8
2021
Statut:
epublish
Résumé
Chronic aflatoxin (AF) exposure has been shown to occur at high levels in children from sub-Saharan Africa (SSA), and has been associated with growth retardation and immune dysfunction. Our objective was to investigate the impact of AF exposure on immune development in early infancy using thymic size and antibody (Ab) response to vaccination as indicators of immune function. A total of 374 infants born between May 2011 and December 2012 were enrolled into the current study. These infants were recruited from a larger, randomised trial examining the impact of nutritional supplementation of mothers and infants on infant immune development (the Early Nutrition and Immune Development Trial). Thymic size (Thymic Index, TI) was measured by sonography at 1 week, 8 weeks, 24 weeks and 52 weeks of infant age. Infants were given the diphtheria-tetanus-pertussis (DTP) vaccine at 8 weeks, 12 weeks and 16 weeks of age, and Ab responses to each vaccine measured at 12 weeks and 24 weeks of age. AF-albumin (AF-alb) adduct levels in infant blood were measured by ELISA as the biomarker of AF exposure. The geometric mean (GM) level of AF-alb increased with age. Only half of infants had detectable AF-alb with a GM of 3.52 pg/mg at 24 weeks, increasing to 25.39 pg/mg at 52 weeks, when 98% of infants had AF-alb >limit of detection. Significant negative association of AF-alb level with TI was seen in infants during the first 24 weeks, especially at 8 weeks of age (p<0.001), which is the time point of fastest thymus growth. There were no associations between AF exposure level and Ab response to pertussis and tetanus, but a significant positive correlation was observed between AF-alb level and Ab titre to diphtheria (p<0.005). High levels of AF exposure during early infancy may impact on infant immune development. ISRCTN49285450.
Sections du résumé
BACKGROUND
Chronic aflatoxin (AF) exposure has been shown to occur at high levels in children from sub-Saharan Africa (SSA), and has been associated with growth retardation and immune dysfunction. Our objective was to investigate the impact of AF exposure on immune development in early infancy using thymic size and antibody (Ab) response to vaccination as indicators of immune function.
METHODS
A total of 374 infants born between May 2011 and December 2012 were enrolled into the current study. These infants were recruited from a larger, randomised trial examining the impact of nutritional supplementation of mothers and infants on infant immune development (the Early Nutrition and Immune Development Trial). Thymic size (Thymic Index, TI) was measured by sonography at 1 week, 8 weeks, 24 weeks and 52 weeks of infant age. Infants were given the diphtheria-tetanus-pertussis (DTP) vaccine at 8 weeks, 12 weeks and 16 weeks of age, and Ab responses to each vaccine measured at 12 weeks and 24 weeks of age. AF-albumin (AF-alb) adduct levels in infant blood were measured by ELISA as the biomarker of AF exposure.
RESULTS
The geometric mean (GM) level of AF-alb increased with age. Only half of infants had detectable AF-alb with a GM of 3.52 pg/mg at 24 weeks, increasing to 25.39 pg/mg at 52 weeks, when 98% of infants had AF-alb >limit of detection. Significant negative association of AF-alb level with TI was seen in infants during the first 24 weeks, especially at 8 weeks of age (p<0.001), which is the time point of fastest thymus growth. There were no associations between AF exposure level and Ab response to pertussis and tetanus, but a significant positive correlation was observed between AF-alb level and Ab titre to diphtheria (p<0.005).
CONCLUSIONS
High levels of AF exposure during early infancy may impact on infant immune development.
TRIAL REGISTRATION NUMBER
ISRCTN49285450.
Identifiants
pubmed: 34285011
pii: bmjopen-2021-048688
doi: 10.1136/bmjopen-2021-048688
pmc: PMC8292809
doi:
Substances chimiques
Aflatoxins
0
Antibodies, Bacterial
0
Diphtheria-Tetanus-Pertussis Vaccine
0
Banques de données
ISRCTN
['ISRCTN49285450']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e048688Subventions
Organisme : Medical Research Council
ID : MC-A760-5Q×00
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMC Med. 2019 Feb 18;17(1):38
pubmed: 30773140
Biomarkers. 2014 Aug;19(5):430-5
pubmed: 24902045
Clin Diagn Lab Immunol. 2005 Sep;12(9):1057-62
pubmed: 16148171
Int Immunol. 2005 Jun;17(6):807-14
pubmed: 15944194
PLoS One. 2014 Apr 08;9(4):e94440
pubmed: 24714096
Int J Epidemiol. 2014 Feb;43(1):216-23
pubmed: 24366492
Toxicol Appl Pharmacol. 2008 Sep 1;231(2):142-9
pubmed: 18501398
Lancet Glob Health. 2017 Feb;5(2):e208-e216
pubmed: 28104187
Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):555-61
pubmed: 8268773
J Pediatr. 2008 Nov;153(5):683-8, 688.e1-3
pubmed: 18589444
PLoS Med. 2019 Aug 6;16(8):e1002854
pubmed: 31386660
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1653-7
pubmed: 18628416
Vet Hum Toxicol. 1996 Oct;38(5):333-6
pubmed: 8888534
IARC Monogr Eval Carcinog Risks Hum. 2002;82:1-556
pubmed: 12687954
Trop Med Int Health. 2000 Dec;5(12):837-41
pubmed: 11169271
Trop Med Int Health. 2014 Mar;19(3):348-354
pubmed: 24372685
Cancer Epidemiol Biomarkers Prev. 1996 Mar;5(3):179-89
pubmed: 8833618
Am J Vet Res. 1986 Sep;47(9):2062-7
pubmed: 3767113
Environ Health Perspect. 2004 Sep;112(13):1334-8
pubmed: 15345349
Lancet. 2005 Jun 4-10;365(9475):1950-6
pubmed: 15936422
BMC Public Health. 2018 Nov 09;18(1):1247
pubmed: 30413157
Food Chem Toxicol. 2018 Jan;111:356-362
pubmed: 29175577
Acta Paediatr. 2003 Sep;92(9):1014-20
pubmed: 14599061
Environ Health Perspect. 2003 Feb;111(2):217-20
pubmed: 12573908
Int J Cancer. 2000 Apr 1;86(1):1-7
pubmed: 10728587
BMC Pregnancy Childbirth. 2012 Oct 11;12:107
pubmed: 23057665
Eur Radiol. 1996;6(5):700-3
pubmed: 8934137
Food Saf (Tokyo). 2016 Mar 30;4(1):14-27
pubmed: 32231900
J Immunol Methods. 2008 Jun 1;335(1-2):79-89
pubmed: 18407287
Int J Environ Res Public Health. 2017 Jan 13;14(1):
pubmed: 28098787
Acta Paediatr. 2002;91(6):698-703
pubmed: 12162605
Nat Toxins. 1992;1(2):100-5
pubmed: 1344903
Pediatr Allergy Immunol. 2004 Apr;15(2):127-32
pubmed: 15059188
Clin Dev Immunol. 2008;2008:790309
pubmed: 18695741
J Toxicol Environ Health B Crit Rev. 2000 Apr-Jun;3(2):109-43
pubmed: 10834078
Int J Mol Sci. 2014 Apr 02;15(4):5649-62
pubmed: 24699046
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2020 Dec;37(12):2123-2134
pubmed: 33026957
Int J Epidemiol. 2003 Aug;32(4):556-62
pubmed: 12913029
BMJ. 2002 Jul 6;325(7354):20-1
pubmed: 12098724
Avian Pathol. 1997;26(2):317-25
pubmed: 18484263
Int J Epidemiol. 2007 Oct;36(5):1119-25
pubmed: 17576701